Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children
On
Paris et Lyon, le 9 juin 2022
ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children
Paris and Lyon, June 9th, 2022 – ORPHELIA Pharma and Gustave Roussy jointly announce today the publication in the scientific journal Pharmaceuticals of the work related to the development of the first temozolomide oral suspension for the treatment of young children and adults with cancer and presenting difficulties to swallow temozolomide capsules (Annereau M. et al., Pharmaceuticals, 2022).
“Since 2015, we have been manufacturing a liquid temozolomide hospital compounded formulation to address the needs of young patients treated in our hospital and a few partner centers,” explains Maxime Annereau, pharmacist at Gustave Roussy and the originator of this project. "In collaboration with ORPHELIA Pharma, we carried out the necessary research work to optimize the physico-chemical properties and the stability of the suspension. Then we conducted a palatability study in order to select the aroma capable of covering the bitterness of temozolomide in the most efficient way. The development of this concentrated suspension has made it possible to obtain a form adapted to the needs of patients and caregivers”, he adds.
"The work done in collaboration with our partner Gustave Roussy led to a prototype of KIMOZO®, an industrialized and patented version of this drinkable and highly concentrated suspension. KIMOZO® is currently in an advanced phase of clinical development,” says Jeremy Bastid, Chief Development Officer of ORPHELIA Pharma. “Temozolomide is an essential drug in the management of many pediatric cancers, including relapsed or refractory neuroblastoma which unfortunately affects very young children. Thanks to the results of this collaboration, we intend to make this pediatric formulation available to patients soon,” he concludes.
About KIMOZO® 40 mg/ml
KIMOZO® 40 mg/ml is a liquid, taste-masked and ready-to-use oral formulation of temozolomide developed in collaboration between the pharmacists and clinicians of Gustave Roussy and the development team of ORPHELIA Pharma. The formulation of KIMOZO® has been covered by a patent application in Europe and in the US.
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.
Last press releases
-
Gold september: two new research programmes launched to tackle childhood cancers
Two of Gustave Roussy’s four new medical and scientific programmes are dedicated to childhood cancers. The first, DECRIPT, aims to improve understanding of the role played by genetics in the development of certain childhood cancers, as well as second cancers that may occur in adulthood. The second, INSPIRE, will draw on the knowledge and techniques already developed at the Institute to create organoids, with the aim of deciphering the mechanisms underlying metastasis and resistance to treatment.
-
Prof. Fabrice Barlesi reappointed at the head of Gustave Roussy, the leading cancer center in France and Europe
By order of Ms. Stéphanie Rist, Minister of Health, Families, Autonomy and Persons with Disabilities, dated 27 July 2026, Professor Fabrice Barlesi has been reappointed as Director General of Gustave Roussy, effective 1 August 2026. At the helm of the Institute for five more years, Prof. Barlesi will continue the transformations undertaken during his first term. This renewal reflects the confidence placed in the project led by the institution to accelerate progress in the fight against cancer, foster and support the development of innovations set to change the future of oncology, and strengthen the influence of one of the world's leading cancer centers.
-
Route du Rhum 2026 Jean Le Cam and Christophe Rateau to sail for Gustave Roussy
For the Route du Rhum - Destination Guadeloupe 2026, Jean Le Cam and Christophe Rateau will sail under the colors of Gustave Roussy, the leading cancer center in France and Europe. Competing respectively in the Vintage and Class40 categories, the two skippers will carry the Institute's mission to the general public, supporting cancer research and raising awareness of prevention, innovation and patient care.
-
Owkin and Gustave Roussy partner to bring K Pro into real-world clinical practice
Owkin and Gustave Roussy, Europe's leading cancer center, today announced a partnership to test K Pro directly within the hospital's real-world clinical and research workflows.
